

For media and investors only

3rd ImmunoSkin Meeting

Almirall's 2024 ImmunoSkin conference hosts leading experts in inflammatory skin conditions to advance science and treatment options

- The third edition of ImmunoSkin underscored Almirall's commitment to advancing the scientific understanding of skin and its diseases, and to pioneering innovation in medical dermatology and strengthening collaboration within the medical community.
- The conference highlighted new therapeutic strategies and facilitated exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates, providing novel insights into disease management.
- The event also addressed other inflammatory skin conditions such as chronic spontaneous urticaria, localized scleroderma, and hidradenitis suppurativa, with a focus on holistic patient care.

BARCELONA, Spain. October 28th, 2024 – Almirall, a global pharmaceutical company dedicated to medical dermatology, successfully hosted **ImmunoSkin, its annual scientific conference focused on chronic inflammatory skin conditions**. This year's event, held from October 26 to 27, brought together leading international experts to discuss the latest scientific advancements and innovative treatments for inflammatory skin conditions and was chaired by **Dr. Diamant Thaçi**, Director of the Institute and Comprehensive Centre for Inflammation Medicine in Lübeck, Germany.

The third edition of ImmunoSkin underscored Almirall's long-standing commitment to advancing the scientific understanding of skin and skin conditions, and its role in collaborating with leading experts in the dermatology community to develop novel treatment options. Leading experts discussed the **latest breakthroughs in biological therapies**, highlighting the crucial role of IL-13 in atopic dermatitis and the integration of novel biologics into current treatment guidelines. Sessions highlighted new therapeutic strategies and explored the **biological mechanisms of psoriasis** through clinical case studies and expert debates, providing innovative insights into disease management.

The event also addressed other inflammatory skin conditions, such as **atopic dermatitis, chronic spontaneous urticaria, localized scleroderma, and hidradenitis suppurativa**, with a focus on holistic approaches to patient care. Presentations emphasized the importance of personalized treatment options and the latest research on the microbiome and intermittent fasting in managing chronic inflammatory skin diseases.

ImmunoSkin 2024 showcased significant scientific advances and also reinforced Almirall's dedication to improving patient outcomes through innovative research and collaboration with the global medical community.

Dr. **Diamant Thaçi**, chair of the event, remarked, *“ImmunoSkin serves as an essential platform for advancing our understanding of autoimmune skin diseases. By bringing together leading experts in a specialised conference dedicated to inflammatory skin conditions, we foster collaboration and share groundbreaking insights that will ultimately enhance patient care.”*

Volker Koscielny, M.D., Chief Medical Officer at Almirall, added, *“Bringing together clinicians and international thought leaders in Dermatology during Almirall’s ImmunoSkin conference allows for a deep exchange around innovation and areas of unmet need. These meetings have an important place to nurture international collaborations and bear testimony to Almirall’s commitment to medical Dermatology”*

Almirall celebrating 80 years of innovation

2024 marks a significant **milestone for Almirall as the company celebrates 80 years of innovation and commitment to delivering impactful solutions to help improve patients’ lives**. With a rich history in the pharmaceutical industry and a strong focus on medical dermatology, Almirall has built a robust pipeline addressing various diseases and using different therapeutic modalities. Leading innovating in medical dermatology is enabled by Almirall’s close collaboration with the dermatology community and patient-centric mindset. Celebrating its 80th anniversary, Almirall reaffirms its dedication to advancing skin science and developing novel treatments to benefit patients and the dermatology community around the world.

For more information about Almirall’s 80th-anniversary celebrations, visit almirall80years.com

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: *to transform the patients’ world by helping them realize their hopes and dreams for a healthy life*. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit <https://www.almirall.com/>

Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173

Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are “forward-looking statements.” These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.